Palvella Therapeutics, Inc.
PVLA
$91.67
$0.080.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.40M | 11.63M | 8.97M | 5.94M | 4.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.66M | 26.55M | 20.21M | 14.10M | 11.15M |
| Operating Income | -31.66M | -26.55M | -20.21M | -14.10M | -11.15M |
| Income Before Tax | -32.95M | -28.38M | -23.08M | -17.43M | 7.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.95 | -28.38 | -23.08 | -17.43 | 7.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.95M | -28.38M | -23.08M | -17.43M | 7.06M |
| EBIT | -31.66M | -26.55M | -20.21M | -14.10M | -11.15M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.93 | -5.84 | -7.45 | -8.25 | -6.84 |
| Normalized Basic EPS | -1.96 | -3.51 | -4.45 | -4.88 | -4.84 |
| EPS Diluted | -2.93 | -5.84 | -7.45 | -8.25 | -6.84 |
| Normalized Diluted EPS | -1.96 | -3.51 | -4.45 | -4.88 | -4.84 |
| Average Basic Shares Outstanding | 44.14M | 34.85M | 25.57M | 16.32M | 11.03M |
| Average Diluted Shares Outstanding | 44.14M | 34.85M | 25.57M | 16.32M | 11.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |